Avinger CE marks Wildcat for PAD
This article was originally published in Clinica
Executive Summary
US medtech firm Avinger has CE marked its Wildcat catheter for sale in Europe. The device is intended for use in endovascular procedures for the treatment of peripheral artery disease (PAD), by creating a channel in blocked peripheral vessels. It may also be used to aid placement of conventional guidewires beyond stenotic lesions, prior to percutaneous intervention. Avinger will start selling the catheter in some European countries by the end of the second quarter of 2011. Wildcat is available in the US as a guidewire support catheter. Avinger (Redwood City, California) is conducting an 88-patient study, CONNECT, evaluating Wildcat for crossing chronic total occlusions in femoropopliteal lesions, in the US. Initial results are expected next week.